2003 Documentation FDA Labelling 
The Checkup by Singlecare
APRIL 17, 2024
Mounjaro (tirzepatide) is an injectable medication prescribed for Type 2 diabetes mellitus, which some doctors may prescribe off-label for weight loss. Legislation passed in 2003 prohibits Medicare from covering drugs prescribed specifically for weight loss, and while Medicaid has more flexibility here, not every state will cover them.
The FDA Law Blog
OCTOBER 18, 2022
On October 17, 2022, FDA published the list of CDRH proposed guidances for FY 2023 (see here ). These are documents on the A-list, a list of prioritized documents that FDA intends to publish during FY2023. FDA published draft guidances for these topics in December 2021 ( here and here ).
ISPE
MAY 10, 2023
Although the pharmaceutical industry has consistently improved manufacturing processes 3 in compliance with good manufacturing practices, 4 there are documented deviations from good practices 5 including the continued falsification of medicines. 5 (2003): 395–413. van Dorp, and J. Managing Traceability Information in Manufacture.”
Expert insights. Personalized for you.
98 
Let's personalize your content